Novel involvement of the immunomodulator AS101 in IL-10 signaling, via the tyrosine kinase Fer

Annals of the New York Academy of Sciences

Volumn 1095, Issue , 2007, Pages 240-250

  Hayun, Rami ^a   Shpungin, Sali ^a   Malovani, Hana ^a   Albeck, Michael ^a   Okun, Eitan ^a   Nir, Uri ^a   Sredni, Benjamin ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

AS101; Fer; IL 10; Mononuclear cell; PBMC; Stat3; Tyrosine kinase

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; IMMUNOMODULATING AGENT; PROTEIN TYROSINE KINASE; RECOMBINANT INTERLEUKIN 10; STAT3 PROTEIN; TYROSINE KINASE FER; UNCLASSIFIED DRUG; AMMONIUM TRICHLORO(DIOXOETHYLENE O,O' )TELLURATE; AMMONIUM TRICHLORO(DIOXOETHYLENE-O,O'-)TELLURATE; ETHYLENE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; PROTO ONCOGENE PROTEIN C FES FPS; PROTO-ONCOGENE PROTEIN C-FES-FPS;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; ARTICLE; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; MONONUCLEAR CELL; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; CELLS, CULTURED; ETHYLENES; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 34247897062     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1397.028     Document Type: Conference Paper

References (32)

1. MOORE, K.W. et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
2. + cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose dependent fashion. J. Immunol. 171: 2270-2278.
3. BOEHLER, A. 2002. The role of interleukin-10 in lung transplantation. Transpl. Immunol. 19: 121-124.
4. AWASTHI, A. et al. 2004. Immune response to Leishmania infection. Indian J. Med. Res. 119: 238-258.
5. SREDNI, B. et al. 2004. Ammonium trichloro(dioxoethylene- o,o′)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 64: 1843-1852.
6. DE VITA, F. et al. 2000. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117: 365-373.
7. BLAY, J.Y. et al. 1993. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82: 2169-2174.
8. FORTIS, C. et al. 1996. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 104: 1-5.
9. GALIZIA, G. et al. 2002. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol. 102: 169-178.
10. FINBLOOM, D.S. et al. 1995. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. 155: 1079-1090.
11. PEDRANZINI, L. et al. 2004. Stat3 is required for the development of skin cancer. Clin. Invest. 114: 619-622.
12. LEVY, D.E. et al. 2002. What does Stat3 do? J. Clin. Invest. 109: 1143-1148.
13. DARNELL, J.E., JR. 1997. STATs and gene regulation. Science 277: 1630-1635.
14. LEVY, D.E. et al. 2002. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3: 651-662.
15. BROMBERG, J. 2002. Stat proteins and oncogenesis. J. Clin. Invest. 109: 1139-1142.
16. WEBER-NORDT, R.M. et al. 1996. Stat3 recruitment by two distinct ligand-induced tyrosine phosphorylated docking sites in the IL-10 receptor intracellular domain. J. Biol. Chem. 271: 27954-27961.
17. TAKEDA, K. et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
18. KENNEDY, R.J. et al. 2000. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br. J. Surg.87(10) : 1346-1351.
19. ALLARD, P. et al. 2000. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Mol. Cell Endocrinol. 159: 63-77.
20. PRIEL-HALACHMI, S. et al. 2000. FER kinase activation of Stat3 is determined by the N-terminal sequence. J. Biol. Chem. 275: 28902-28910.
21. TALER, M. et al. 2003. Fer is a downstream effector of insulin and mediates the activation of signal transducer and activator of transcription 3 in myogenic cells. Mol. Endocrinol. 17: 1580-1592.
22. SREDNI, B. et al. 1987. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 330: 173-176.
23. ROSENBLATT-BIN, H. et al. 1998. The immunomodulator AS101 restores T(H1) type of response suppressed by Babesia rodhaini in BALB/c mice. Cell Immunol. 184: 12-25.
24. KALECHMAN, Y. et al. 1997. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J. Immunol. 159: 2658-2667.
25. KALECHMAN, Y. et al. 2002. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J. Immunol. 169: 384-392.
26. SREDNI, B. et al. 1996. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J. Natl. Cancer Inst. 88: 1276-1284.
27. KALECHMAN, Y. et al. 2000. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int. J. Cancer 86: 281-288.
28. SREDNI, B. et al. 1995. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J. Clin. Oncol. 13: 2342-2353.
29. BOUGANIM-HAYUN, M. et al. 2002. The synergistic activity of AS101 and PMA on HL-60 cells differentiation: mechanism of action. In Proceedings of the 2nd International Conference on: Tumor Microenvironment: Progression, Therapy and Prevention. I.P. Witz, Ed.: 221-228. Monduzzi Editor S.p.A. - MEDIMOND Inc. Baden, Austria.
30. STRASSMANN, G. et al. 1997. The immunomodulator AS-101 inhibits IL-10 release and augments TNF alpha and IL-1 alpha release by mouse and human mononuclear phagocytes. Cell Immunol. 176: 180-185.
31. KALECHMAN, Y. et al. 2004. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3. J. Biol. Chem. 279: 24724-24732.
32. ZALDIVAR, F. et al. 2006. Constitutive pro- and anti-inflammatory cytokine and growth factor response to exercise in leukocytes. J. Appl. Physiol. 100: 1124-1133.